XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 27, 2020
Aug. 31, 2020
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2020
Dec. 31, 2022
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Accounts receivable     $ 7,026     $ 3,678
Novartis Institutes for BioMedical Research, Inc.            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Capitalized contract cost, amortization expense     200 $ 100    
Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Proceeds from collaborators   $ 75,000        
Collaborative arrangement transaction price $ 95,100          
Collaborative arrangement, license fee 75,000          
Collaborative arrangement estimated reimbursable service costs $ 20,100          
Accounts receivable     2,100     2,200
Deferred revenue     $ 1,900     $ 9,600
Financial advisory fees         $ 1,500  
Percent of initial recognition         2.00%